References
- Zmaili MA , AlzubiJM, KocyigitDet al. A contemporary 20-year Cleveland Clinic experience of nonbacterial thrombotic endocarditis: etiology, echocardiographic imaging, management, and outcomes. Am. J. Med., 134(3), 361–369 (2021).
- González QA , CandelaMJ, VidalC, RománJ, AramburoP. Non-bacterial thrombotic endocarditis in cancer patients. Acta Cardiol., 46(1), 1–9 (1991).
- Rahouma M , KhairallahS, DabshaAet al. Lung cancer as a leading cause among paraneoplastic non-bacterial thrombotic endocarditis: a meta-analysis of individual patients’ data. Cancers, 15(6), 1848 (2023).
- Mazokopakis E , PeriklisS, IoannisSK. Nonbacterial thrombotic endocarditis (marantic endocarditis) in cancer patients. Cardiovasc. Hematol. Disord. Drug Targets, 10(2), 84–86 (2010).
- El-Shami K , GriffithsE, StreiffM. Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment. Oncologist, 12(5), 518–523 (2007).
- Li A , GarciaDA, LymanGH, CarrierM. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb. Res., 173, 158–163 (2019).
- Rossel A , Robert-EbadiH, CombescureCet al. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: a systematic review and network meta-analysis. PLOS ONE, 14(3), e0213940 (2019).
- Schrag D , UnoH, RosovskyRet al. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA, 329(22), 1924–1933 (2023).
- Lyman GH , CarrierM, AyCet al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv., 5(4), 927–974 (2021).
- Falanga A , AyC, DiNisio M. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann. Oncol., 34(5), 452–467 (2023).